Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing

RegulatoryTavneosNegative

AI Analysis

Summary

Amgen's Tavneos (avacopan) is no longer available for new patients in the UK under CSL Vifor's marketing authorization, while the company awaits an FDA hearing regarding concerns raised about the drug in the U.S. market.

Outcome Details

Drug no longer available for new patients in UK; FDA hearing awaited

Importance:6/10

Sentiment:

-0.60

regulatorymarket_accessUKFDAtavneosavacopan

Related Companies

$AMGN

Read the original article

Published by BioSpace on September 2, 2026 11:38 AM

Read Original